NRIX — Nurix Therapeutics, Inc.
NRIX dilution and offerings
- Float: 98.2M shares
$25.70-4.10%
Last close: · regular session
After-hours $25.74 +0.16% ·
Last 60 sessions
Float: 98.2M shares. Latest SEC filing: 4 on Nov 3, 2026. NRIX closed at $25.70 (-4.10%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NRIX in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 286
- Website: https://www.nurixtx.com
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Latest SEC filings for NRIX
Latest NRIX news
- Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways Read article
- Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates Read article
- Nurix Therapeutics GAAP EPS of $4.73 beats by $1.64, revenue of $673.1M beats by $193.58M Read article
- Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Read article
- Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia Read article
- Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.